B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 8.25 HKD -2.02% Market Closed
Market Cap: 3.3B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Biocytogen Pharmaceuticals Beijing Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Total Current Liabilities
ÂĄ577.6m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Current Liabilities
ÂĄ4.1B
CAGR 3-Years
23%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
71%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Liabilities
ÂĄ297.7m
CAGR 3-Years
49%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
3.3B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
11.01 HKD
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Total Current Liabilities?
Total Current Liabilities
577.6m CNY

Based on the financial report for Dec 31, 2023, Biocytogen Pharmaceuticals Beijing Co Ltd's Total Current Liabilities amounts to 577.6m CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
21%

Over the last year, the Total Current Liabilities growth was -5%. The average annual Total Current Liabilities growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 21% over the past three years .

Back to Top